Literature DB >> 17652759

Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration.

Sten Kjellstrom1, Ronald A Bush, Yong Zeng, Yuichiro Takada, Paul A Sieving.   

Abstract

PURPOSE: The authors characterized the natural history of a retinoschisin gene knockout (Rs1h-KO) mouse model and evaluated the long-term effects of retinal rescue after AAV(2/2)-CMV-Rs1h gene delivery.
METHODS: Full-field scotopic electroretinograms (ERGs) were recorded from 44 male hemizygous Rs1h-KO and 44 male wild-type (WT) C57BL/6J mice at six ages between 1 and 16 months. Retinal morphometry included outer segment layer (OSL) width, photoreceptor cell count, and grading of schisis cavity severity. One eye each of seven Rs1h-KO mice at age 14 days was injected with AAV(2/2)-CMV-Rs1h, and retinal histology and ERG findings at 14 months were analyzed.
RESULTS: The outer nuclear layer (ONL) of 1-month-old Rs1h-KO mice was disorganized but had nearly normal cell counts. The OSL was thinned, rod outer segments were misaligned, and abundant schisis cavities spanned the inner nuclear and outer plexiform layers in all retinas. ERG a- and b-wave amplitudes at this age were reduced by 33% and 50%, respectively. ERG and ONL cell numbers decreased further between 1 and 16 months, with unequal changes in the a- and b-waves with age. The a-wave reduction correlated well with the steady decline in ONL cell number, whereas a rapid decline in the b-wave and a (b/a-wave) ratio less than in WT were associated with increasing severity of schisis cavities at young ages. At 4 months, the cavities were maximal, but they coalesced and disappeared at older ages. The (b/a-wave) ratio was inversely correlated with cavity severity across all ages (r = -0.74; P < 0.0001; n = 22). Considerable heterogeneity was observed at each age in the ERG amplitudes and retinal morphology. Mice injected with AAV-Rs1h at 14 days showed considerable structural and functional rescue at age 14 months, including improved rod outer and inner segment integrity, less photoreceptor cell loss, and larger ERG amplitudes compared with untreated fellow eyes.
CONCLUSIONS: The ERG of the Rs1h-KO mouse at early ages reflects disruption of photoreceptor and second-order neuron function. In mid to late ages, the ERG decline reflects primarily photoreceptor degeneration. The Rs1h-KO mouse is consistent with human clinical X-linked juvenile retinoschisis (XLRS) in showing schisis cavities, which affect primarily the b-wave, the regression of schisis cavities at older ages, and a considerable range in phenotypic severity across individuals. This mouse model also indicates the critical roll of RS-protein in photoreceptor survival consistent with decreased a-waves in some patients with XLRS. Long-term rescue of retinal morphology and function by AAV-Rs1h gene transfer may provide a basis for considering intervention in the homologous human XLRS condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652759     DOI: 10.1167/iovs.07-0203

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  57 in total

Review 1.  Gene therapy for ocular diseases.

Authors:  Melissa M Liu; Jingsheng Tuo; Chi-Chao Chan
Journal:  Br J Ophthalmol       Date:  2010-08-23       Impact factor: 4.638

2.  Tyrosinase is the modifier of retinoschisis in mice.

Authors:  Britt A Johnson; Brian S Cole; Eldon E Geisert; Sakae Ikeda; Akihiro Ikeda
Journal:  Genetics       Date:  2010-09-27       Impact factor: 4.562

3.  Transgenic expression of constitutively active RAC1 disrupts mouse rod morphogenesis.

Authors:  Hongman Song; Ronald A Bush; Camasamudram Vijayasarathy; Robert N Fariss; Sten Kjellstrom; Paul A Sieving
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-25       Impact factor: 4.799

4.  Gene delivery to the retina: from mouse to man.

Authors:  Jean Bennett; Daniel C Chung; Albert Maguire
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

Review 5.  A comprehensive review of retinal gene therapy.

Authors:  Shannon E Boye; Sanford L Boye; Alfred S Lewin; William W Hauswirth
Journal:  Mol Ther       Date:  2013-01-29       Impact factor: 11.454

6.  R102W mutation in the RS1 gene responsible for retinoschisis and recurrent glaucoma.

Authors:  Xiu-Feng Huang; Chang-Sen Tu; Dong-Jun Xing; De-Kang Gan; Ge-Zhi Xu; Zi-Bing Jin
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

7.  A novel deletion mutation in RS1 gene caused X-linked juvenile retinoschisis in a Chinese family.

Authors:  Y Huang; L Mei; B Gui; W Su; D Liang; L Wu; Q Pan
Journal:  Eye (Lond)       Date:  2014-08-29       Impact factor: 3.775

8.  ERG variability in X-linked congenital retinoschisis patients with mutations in the RS1 gene and the diagnostic importance of fundus autofluorescence and OCT.

Authors:  Agnes B Renner; Ulrich Kellner; Britta Fiebig; Elke Cropp; Michael H Foerster; Bernhard H F Weber
Journal:  Doc Ophthalmol       Date:  2007-11-07       Impact factor: 2.379

9.  Synaptic pathology in retinoschisis knockout (Rs1-/y) mouse retina and modification by rAAV-Rs1 gene delivery.

Authors:  Yuichiro Takada; Camasamudram Vijayasarathy; Yong Zeng; Sten Kjellstrom; Ronald A Bush; Paul A Sieving
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08       Impact factor: 4.799

10.  Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.

Authors:  Susie E Barker; Cathryn A Broderick; Scott J Robbie; Yanai Duran; Mythili Natkunarajah; Prateek Buch; Kamaljit S Balaggan; Robert E MacLaren; James W B Bainbridge; Alexander J Smith; Robin R Ali
Journal:  J Gene Med       Date:  2009-06       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.